关键词: 纤溶酶原激活物抑制物, 胰激肽原酶, 非胰岛素依赖型, 纤溶酶原激活剂, 糖尿病

Abstract: To investigate the relationship of chronic diabetic vascular complication and plasma t-PA and PAI-1 levels in type 2 diabetes and the effect of pancreatic kallikrein（TPK）on them. Methods88 patients with type 2 diabetes and 30 healthy controls were recruited into the study. Plasma t-PA and PAI-1 levels were determined by ELISA. Measurements were also carried out before and after the interfered treatment of TPK. ResultsCompared with the healthy controls, the diabetes patients showed a decreased plasma t-PA level and an increased PAI-1 level (P＜0.05 or＜0.01). The plasma t-PA level in diabetes patients with vascular complications was lower and the PAI-1 level was higher than those without vascular complications (both P＜0.01). The plasma t-PA level increased and the PAI-1 level decreased in diabetes patients after the treatment of TPK. tPA had a negative relationship with plasma TG and LDL-c levels, and PAI-1 had positive relationships with BMI, plasma TG and LDL-c levels, FBG, SBP and HbA1c. ConclusionPlasminogen dysfunction is an essential factor in the occurrence and development of diabetic vascular complications. The interfered treatment of TPK may prevent the development of type 2 diabetes and its vascular complications.

Key words: Type 2 diabetes, Tissue plasminogen activator, Plasminogen activator inhibitor-1, Pancreatic kallikrein